[Early immunomodulatory treatment of multiple sclerosis: pros and cons].
Early immunomodulatory treatment of multiple sclerosis has raised great hopes, especially among MS patients and their families. However, there are considerable differences of opinion among medical professionals, particularly as regards the economic aspect of the therapy (often undertaken before any definite diagnosis is made). The findings documenting early irreversible axonal lesions and brain atrophy in MS, as well as results of clinical studies suggest that early immunomodulatory treatment is the method of choice, even if critical arguments are taken into account.
Wender
Mieczysław
M
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D001284:Atrophy / Q000473:pathology; D001369:Axons / Q000473:pathology; D001921:Brain / Q000473:pathology; D000068717:Glatiramer Acetate; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a